STOCK TITAN

Xencor, Inc. - XNCR STOCK NEWS

Welcome to our dedicated page for Xencor news (Ticker: XNCR), a resource for investors and traders seeking the latest updates and insights on Xencor stock.

Xencor, Inc. (XNCR) is a leading clinical-stage biopharmaceutical company headquartered in the United States, dedicated to the discovery and development of engineered monoclonal antibody and protein therapeutics. The primary goal of Xencor is to address severe and life-threatening diseases that currently have unmet medical needs, such as autoimmune diseases, asthma, and various forms of cancer.

Xencor leverages its proprietary XmAb® technology platform to enhance the natural immune functions of antibodies while maintaining a high degree of similarity to natural antibodies (over 99.5% identity). This innovative approach allows Xencor to create biotherapeutics that are more potent, safer, and longer-lasting, thereby improving patient outcomes and quality of life.

One of the key strengths of Xencor's XmAb technology is its ability to dramatically augment the immune functions of antibodies. This has resulted in a robust pipeline of product candidates, including eight in human clinical trials. Notable candidates in clinical development include XmAb5871 and XmAb7195, with several others such as XmAb14045 and XmAb662 in the pre-clinical stage. These candidates are being developed both by Xencor and in collaboration with pharmaceutical partners.

Financially, Xencor generates revenue through research and development collaborations and the licensing of its internally developed drug candidates. This collaborative approach not only advances their pipeline but also brings in essential funding to support ongoing and future projects.

Recently, Xencor has made significant strides in expanding its partnerships and advancing its clinical trials. These developments are crucial as they bring the company closer to delivering breakthrough treatments that can transform patient care in various therapeutic areas.

Overall, Xencor, Inc. stands out in the biopharmaceutical industry for its innovative approach to antibody and protein engineering, with a mission to fundamentally improve the treatment of serious diseases and enhance the quality of life for patients around the world.

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.87%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.4%
Tags
conferences earnings
-
Rhea-AI Summary

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company, announced the appointment of Nancy Valente, M.D., as Executive Vice President and Chief Development Officer, effective May 1, 2023. Dr. Valente brings over 20 years of experience in biopharmaceutical product development, previously serving as a senior vice president at Genentech. She has been an independent board member since September 2022 and will now lead Xencor's clinical and medical strategy. Allen Yang, M.D., Ph.D., Chief Medical Officer, will assist during the transition before pursuing other opportunities. Dr. Valente's expertise will support Xencor's efforts to develop its clinical pipeline and deliver effective therapeutics for cancer and autoimmune diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.2%
Tags
management
Rhea-AI Summary

Xencor, Inc. (NASDAQ:XNCR), a biopharmaceutical company focused on engineered antibodies for cancer treatment, presented preclinical data on CD28 bispecific antibodies targeting solid tumor antigens at the AACR Annual Meeting in Orlando, Florida. The study showcased enhanced T cell activation when combined with a CD3 T cell engager. Xencor's XmAb® platform enables rapid creation of bispecific antibodies that stimulate CD28 in the presence of tumor cells. The company is also conducting a Phase 1 study of XmAb808, a bispecific antibody targeting B7-H3 and CD28, demonstrating strong potential for enhanced immune response against tumors. Xencor's innovative technology is designed to improve therapeutic outcomes for patients with advanced solid tumors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.33%
Tags
none
-
Rhea-AI Summary

Xencor, Inc. (NASDAQ:XNCR) announced the upcoming presentation of preclinical data on its XmAb® CD28 bispecific antibody programs at the American Association for Cancer Research (AACR) Annual Meeting from April 14-19, 2023, in Orlando, Florida. The data aims to enhance T cell activation in solid tumors by targeting ligands that are typically absent in tumor cells. The platform focuses on noteworthy solid tumor targets such as CEACAM5, mesothelin, STEAP1, and Trop-2. This research reflects Xencor's commitment to advancing cancer therapies using its innovative XmAb technology, with an emphasis on the potential for increased efficacy in treating various solid tumors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.25%
Tags
conferences clinical trial
-
Rhea-AI Summary

Xencor, Inc. (NASDAQ:XNCR) reported financial results for Q4 and full year 2022, highlighting ongoing clinical advancements and a focus on its XmAb® drug candidates. The company recorded total revenue of $21.6 million for Q4 2022, down from $154.0 million in Q4 2021, with full-year revenue at $164.6 million, down from $275.1 million. R&D expenses remained steady at $51.5 million for Q4 2022, while G&A expenses rose to $12.8 million. Xencor anticipates ending 2023 with $425 million to $475 million in cash, supporting operations through 2025. The company aims to initiate multiple Phase 1 studies for new therapies later in 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.07%
Tags
Rhea-AI Summary

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company focused on engineered antibodies and cytokines for cancer and autoimmune diseases, will announce its fourth-quarter and full-year 2022 financial results on February 23, 2023, after market close. A conference call to discuss these results and provide a corporate update will occur the same day at 4:30 p.m. ET. The live webcast will be available in the Investors section of their website and archived for 30 days. Xencor has over 20 candidates in clinical development and three marketed medicines through partnerships, utilizing its XmAb technology for novel therapeutic mechanisms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
conferences earnings
-
Rhea-AI Summary

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company, will present at the virtual 2023 SVB Securities Global Biopharma Conference on February 14, 2023, at 3:40 p.m. ET. The presentation will focus on the company's innovative engineered antibodies and cytokines aimed at treating cancer and autoimmune diseases. A live webcast will be available in the Investors section of Xencor's website, with an archived replay accessible for at least 30 days following the event. Xencor is advancing over 20 clinical candidates developed with its XmAb® technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.08%
Tags
conferences
-
Rhea-AI Summary

Xencor, Inc. (NASDAQ:XNCR) has announced its 2023 corporate priorities and clinical updates in oncology and autoimmune diseases. The company is advancing several bispecific antibodies, including plamotamab and vudalimab, focusing on treating solid tumors and B-cell malignancies. Notably, XmAb564, targeting regulatory T cells, shows promise in autoimmune treatments. Xencor maintains a strong financial position with approximately $610 million in cash, projected to fund operations through 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.44%
Tags
none
Rhea-AI Summary

Caris Life Sciences and Xencor, Inc. have expanded their collaboration to research and develop novel XmAb bispecific antibodies aimed at treating cancer. This agreement builds on the initial partnership from August 2022 and will increase the number of targets and cancer types that Caris will investigate using its Caris Discovery platform. Xencor gains exclusive global rights to develop products from up to three discovered targets. Caris will receive an upfront payment and could earn up to $187 million in milestone payments, along with royalties on future sales.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.85%
Tags
none

FAQ

What is the current stock price of Xencor (XNCR)?

The current stock price of Xencor (XNCR) is $24.13 as of December 20, 2024.

What is the market cap of Xencor (XNCR)?

The market cap of Xencor (XNCR) is approximately 1.7B.

What is Xencor, Inc.?

Xencor, Inc. is a clinical-stage biopharmaceutical company focused on developing engineered monoclonal antibody and protein therapeutics for severe and life-threatening diseases.

What is the XmAb technology?

The XmAb technology platform enhances the immune functions of antibodies, making therapeutics more potent, safer, and longer-lasting while maintaining high similarity to natural antibodies.

What are some key products in Xencor's pipeline?

Key products include XmAb5871, XmAb7195, XmAb14045, and XmAb662, with several others in various stages of clinical and pre-clinical development.

How does Xencor generate revenue?

Xencor generates revenue through research and development collaborations and the licensing of its internally developed drug candidates.

Where is Xencor, Inc. based?

Xencor, Inc. is based in the United States.

What diseases does Xencor target?

Xencor targets severe and life-threatening diseases such as autoimmune diseases, asthma, and cancer.

What makes Xencor's biotherapeutics unique?

Xencor's biotherapeutics are unique due to their enhanced potency, safety, and longevity, achieved through the proprietary XmAb technology.

Who are Xencor's partners?

Xencor collaborates with various pharmaceutical partners to develop its antibody product candidates.

What recent achievements has Xencor made?

Xencor has made significant strides in expanding partnerships and advancing clinical trials, bringing them closer to delivering innovative treatments.

What is the primary goal of Xencor?

The primary goal of Xencor is to develop biotherapeutics that improve patient outcomes and quality of life for those suffering from severe and life-threatening diseases.

Xencor, Inc.

Nasdaq:XNCR

XNCR Rankings

XNCR Stock Data

1.71B
68.81M
0.89%
104.54%
5.86%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
PASADENA